---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-066021"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2026-05-26T12:07:16+00:00"
generated_at: "2026-05-26T12:10:28.373549+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine suspends ATM offering program; $43.9M raised to date

## Summary
- Notified TD Cowen of suspension and termination of March 21, 2025 prospectus supplement.
- No further ATM sales until new prospectus or registration statement is filed and effective.
- Sales Agreement with TD Cowen remains in full force and effect.
- Aggregate sales to date: 14,327,365 shares for $43.9M gross proceeds before expenses.

## SEC filing metadata
- accession: 0001104659-26-066021
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2026-05-26T12:07:16+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000110465926066021/0001104659-26-066021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000110465926066021/tm2615565d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-066021
- JSON: https://secwatch.observer/filing/0001104659-26-066021.json
- Plain text: https://secwatch.observer/filing/0001104659-26-066021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.